In response to this challenge, in September of this year SNM launched an innovative
process for integrating imaging biomarkers into phase 1, 2, and 3 clinical trials of new …

Over the past decade, biomarkers have been recognized as a critical element needed to
improve predictability and efficiency in the process of developing more effective, more …

Radioactive imaging agents, like diagnostic drugs generally, undergo a drug development
process that parallels that of therapeutic agents, with similar development times but …

The Critical Path Initiative (CPI) of the US Food and Drug Administration (FDA), initiated in
2004 and updated with a list of opportunities and guidelines, has 2 key premises:(1) imaging …

The objective of this study was to estimate the financial cost of developing new imaging
agents for clinical use and to discuss the effects of these costs on the future clinical imaging …

The process of bringing a new drug to market is complex and has recently necessitated a
new drug-discovery paradigm for the pharmaceutical industry that is both more efficient and …

The FDA, in particular, has written extensively of its vision of the future where imaging
agents of all types will play a pivotal role in speeding up drug development in early clinical …

This special issue of the journal contains contributions from participants of the third La Jolla
meeting (The Magic Bullet: A Century Later). The goal of this meeting was twofold: to review …

There have been many applications of the peaceful use of the atom. Probably none have
been as effective as the radiopharmaceuticals developed to better understand human …

In 2011, new nuclear medicine residency program recommendations included an increased
emphasis on molecular imaging in clinical practice, and the American Board of Nuclear …